Pfizer Aktie

25,55 EUR +0,27 EUR +1,07 %

23.12.2024

STU

26,71 USD ±0,00 USD ±0,00 %

16:57:09

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.145,64 Mrd. EUR

KGV76,67Div. Rendite5,73%

WKN852009

ISINUS7170811035

SymbolPFE

Pfizer Aktien News

Sortieren:Datum Meistgelesen

20.12.24BusinesswireU.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

19.12.24BusinesswirePfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

17.12.24BusinesswirePfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

WerbungPfizer-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

12.12.24BusinesswirePfizer Declares First-Quarter 2025 Dividend

10.12.24BusinesswirePfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

05.12.24BusinesswirePfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS

20.11.24BusinesswirePfizer Announces New Chief Scientific Officer and President, Research & Development

20.11.24BusinesswireEuropean Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

14.11.24BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

04.11.24BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

29.10.24BusinesswirePfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

23.10.24BusinesswireAdvisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

22.10.24BusinesswireU.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease

15.10.24BusinesswireTim Buckley Elected to Pfizer’s Board of Directors

11.10.24BusinesswireU.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

10.10.24BusinesswirePfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial

09.10.24BusinesswirePfizer Declares Fourth-Quarter 2024 Dividend

08.10.24BusinesswirePfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024

25.09.24BusinesswirePfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

20.09.24BusinesswirePfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

17.09.24BusinesswirePfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts

14.09.24BusinesswirePfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

14.09.24BusinesswirePfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

11.09.24BusinesswirePfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024

28.08.24BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

27.08.24BusinesswirePfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare

22.08.24BusinesswirePfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

16.08.24BusinesswirePfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

12.08.24BusinesswirePfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults

31.07.24PR NewswireViiV Healthcare announces positive data demonstrating 2-drug regimen DOVATO is as effective as 3-drug regimen BIKTARVY for maintenance therapy of HIV-1

30.07.24BusinesswirePfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance

25.07.24BusinesswireEuropean Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B

24.07.24BusinesswirePfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate

11.07.24BusinesswirePfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron

09.07.24BusinesswirePfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development

01.07.24BusinesswireCyrus Taraporevala Elected to Pfizer’s Board of Directors

27.06.24BusinesswirePfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

26.06.24BusinesswirePfizer Declares Third-Quarter 2024 Dividend

18.06.24BusinesswirePfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts

Pfizer News

Pfizer News: auf dieser Seite finden Sie alle Pfizer News und Nachrichten zur Pfizer Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Pfizer News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Pfizer News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.